MTA Depletion Proof of Concept in Syngeneic Tumor Models

Delta TpX signed an exclusive license agreement with University of Texas at Austin for a patent portfolio covering DTX-5500 in August 2021

Delta TpX’s first US patent #11118167 has issued

Gjuka et. al., Molecular Cancer Therapeutics 2019 Abstract LB-A18: The frequent tumor deletion of MTAP is a newly recognized potent immune checkpoint that is effectively reversed by a human methylthioadenosine degrading drug candidate.

Learn More >>